These findings were also observed in the sensitivity analysis of IPT-weighted SHR adjusted for calendar year, but in the on-treatment analysis, factor Xa inhibitors were only associated with lower incidence of smoking- and alcohol-related cancers and hematological cancers (S4 and S5 Tables). Here, F10 is linked to hematopoietic and lymphoid cell neoplasm.